Please wait while the formulary information is being retrieved.
EXELON (RIVASTIGMINE)
- Dementia associated with parkinson's disease
- Mild to moderate alzheimer's type dementia
- Moderate to severe alzheimer's type dementia
13.3 mg/24 hour transdermal patch
- Apply 1 patch (13.3 mg) by transdermal route once daily . Do not apply to same area more than once every 14 days.
4.6 mg/24 hour transdermal patch
- Apply 1 patch (4.6 mg) by transdermal route once daily . Do not applyto same area more than once every 14 days.
9.5 mg/24 hour transdermal patch
- Apply 1 patch (9.5 mg) by transdermal route once daily . Do not applyto same area more than once every 14 days.
Patch 13.3 mg/24 hour transdermal
- Apply 1 patch (13.3 mg) by transdermal route once daily . Do not apply to same area more than once every 14 days.
Patch 4.6 mg/24 hr transdermal
- Apply 1 patch (4.6 mg) by transdermal route once daily . Do not applyto same area more than once every 14 days.
Patch 9.5 mg/24 hr transdermal
- Apply 1 patch (9.5 mg) by transdermal route once daily . Do not applyto same area more than once every 14 days.
Dementia associated with parkinson's disease
- Apply 1 patch (13.3 mg) by transdermal route once daily . Do not apply to same area more than once every 14 days.
- Apply 1 patch (13.3 mg) by topical route once daily . Do not apply tosame area more than once every 14 days.
- Apply 1 patch (4.6 mg) by transdermal route once daily . Do not applyto same area more than once every 14 days.
- Apply 1 patch (4.6 mg) by topical route once daily . Do not apply to same area more than once every 14 days.
- Apply 1 patch (9.5 mg) by transdermal route once daily . Do not applyto same area more than once every 14 days.
- Apply 1 patch (9.5 mg) by topical route once daily . Do not apply to same area more than once every 14 days.
Mild to moderate alzheimer's type dementia
- Apply 1 patch (4.6 mg) by transdermal route once daily . Do not applyto same area more than once every 14 days.
- Apply 1 patch (4.6 mg) by topical route once daily . Do not apply to same area more than once every 14 days.
- Apply 1 patch (9.5 mg) by transdermal route once daily . Do not applyto same area more than once every 14 days.
- Apply 1 patch (9.5 mg) by topical route once daily . Do not apply to same area more than once every 14 days.
Moderate to severe alzheimer's type dementia
- Apply 1 patch (13.3 mg) by transdermal route once daily . Do not apply to same area more than once every 14 days.
- Apply 1 patch (13.3 mg) by topical route once daily . Do not apply tosame area more than once every 14 days.
- metoclopramide HCl
- Metozolv Odt
- Reglan
Contraindicated
- None
Severe
Moderate
- Anectine
- dextromethorphan-quinidine
- Nuedexta
- Quelicin
- quinidine gluconate
- quinidine sulfate
- succinylcholine chloride
- None
Contraindicated
- Asthma
- Bradycardia
- Cardiac arrhythmia
- Chronic obstructive pulmonary disease
- Extrapyramidal disease
- Gastrointestinal hemorrhage
- Gastrointestinal ulcer
- Sick sinus syndrome
- Weight loss
Severe
Moderate
- Anorexia
- Diarrhea
- Parkinsonism
- Seizure disorder
- Urinary tract obstructive uropathy
- Vomiting
EXELON (RIVASTIGMINE)
- Dementia associated with parkinson's disease
- Mild to moderate alzheimer's type dementia
- Moderate to severe alzheimer's type dementia
- None
- Diarrhea
- Dizziness
- Dyspepsia
- Hallucinations
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Bradycardia
- Hypertension
- Syncope
- Abdominal pain with cramps
- Anorexia
- Depression
- Drowsy
- Fatigue
- General weakness
- Headache disorder
- Hyperhidrosis
- Insomnia
- Symptoms of anxiety
- Urinary tract infection
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acquired dystonia
- Allergic dermatitis
- Atrial fibrillation
- Atrioventricular block
- Bloody vomit
- Dehydration
- Dyskinesia
- Hepatitis
- Hyponatremia
- Pancreatitis
- Peptic ulcer
- Seizure disorder
- Stevens-johnson syndrome
- Tachycardia
Less Severe
- Acute eruptions of skin
- Aggressive behavior
- Agitation
- Athetoid movements
- Blurred vision
- Chest pain
- Contact dermatitis
- Dyspnea
- Extrapyramidal disease
- Gait abnormality
- Gastroesophageal reflux disease
- Nightmares
- Pharyngitis
- Pruritus of skin
- Sialorrhea
- Skin rash
- Treatment site sequelae
- Tremor
- Urinary incontinence
- Urticaria
- Vertigo
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Rivastigmine
Safety and efficacy not established. Manufacturer does not recommend use.
- 1 Day – 18 Years
- Safety and efficacy not established. Manufacturer does not recommend use.
Rivastigmine
- Severity Level:
2
- Additional Notes: Insufficient human data available; animal data suggest no developmental toxicity
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Rivastigmine
Insufficient data available
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Dementia associated with parkinson's disease | |
G31.83 | Dementia with lewy bodies |
Mild to moderate alzheimer's type dementia | |
G30 | Alzheimer's disease |
G30.0 | Alzheimer's disease with early onset |
G30.1 | Alzheimer's disease with late onset |
G30.8 | Other alzheimer's disease |
G30.9 | Alzheimer's disease, unspecified |
Moderate to severe alzheimer's type dementia | |
G30 | Alzheimer's disease |
G30.0 | Alzheimer's disease with early onset |
G30.1 | Alzheimer's disease with late onset |
G30.8 | Other alzheimer's disease |
G30.9 | Alzheimer's disease, unspecified |
0-9 | A-Z |
---|---|
G30 | Alzheimer's disease |
G30 | Alzheimer's disease |
G30.0 | Alzheimer's disease with early onset |
G30.0 | Alzheimer's disease with early onset |
G30.1 | Alzheimer's disease with late onset |
G30.1 | Alzheimer's disease with late onset |
G30.8 | Other alzheimer's disease |
G30.8 | Other alzheimer's disease |
G30.9 | Alzheimer's disease, unspecified |
G30.9 | Alzheimer's disease, unspecified |
G31.83 | Dementia with lewy bodies |
Formulary Reference Tool